Antecedent Administration of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for SARS‐CoV‐2 (COVID‐19)

Alberto Palazzuoli MD, PhD, FESC1 , Massimo Mancone PhD,2 Gaetano M. De Ferrari MD,3 Giovanni Forleo MD,4 Gioel G. Secco Md, PhD,5 Gaetano M Ruocco MD,6 Fabrizio D’Ascenzo MD, PhD,3 Silvia Monticone MD,7Anita Paggi MD,8 Marco Vicenzi MD,9 Anna G Palazzo MD,10 Maurizio Landolina MD,11 Erika Taravelli MD, 11 Guido Tavazzi MD PhD, 12 Francesco Blasi MD,13 Fabio Infusino MD,2 Francesco Fedele MD,2 Francesco G De Rosa MD14 Michael Emmett, MD,15 Jeffrey M. Schussler, MD, 15 16 17 Kristen M. Tecson, PhD,15 16 17 Peter A. McCullough, MD, MPH 15

[1]  Thomas M Maddox,et al.  Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. , 2020, JAMA cardiology.

[2]  E. Lakatta,et al.  The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. , 2020, JAMA cardiology.

[3]  M. Dawes,et al.  A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019). , 2020, The New Zealand medical journal.

[4]  F. Messerli,et al.  Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? , 2020, Journal of the American Heart Association.

[5]  Lei Liu,et al.  Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients , 2020, medRxiv.

[6]  Joshua D. Brown.  Antihypertensive drugs and risk of COVID-19? , 2020, The Lancet Respiratory Medicine.

[7]  G. Onder,et al.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.

[8]  D. Batlle,et al.  Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? , 2020, Clinical science.

[9]  P. Martinez-Lage,et al.  Sex differences in the aging pattern of renin–angiotensin system serum peptidases , 2017, Biology of Sex Differences.

[10]  K. Denton,et al.  Epochs in the depressor/pressor balance of the renin-angiotensin system. , 2016, Clinical science.

[11]  L. Luo,et al.  Activation of renin–angiotensin–aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[12]  R. Lutter,et al.  Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin‐(1–7) or an angiotensin II receptor antagonist , 2011, The Journal of pathology.

[13]  A. Loeckinger,et al.  Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets , 2010, Critical care medicine.

[14]  Christian Drosten,et al.  Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 , 2009, Journal of Virology.

[15]  Matthew D. Dyer,et al.  Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection , 2009, Journal of Virology.

[16]  Chengsheng Zhang,et al.  Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction. , 2008, The Journal of general virology.

[17]  J. Penninger,et al.  Angiotensin-converting enzyme 2 in lung diseases , 2006, Current Opinion in Pharmacology.